Alzinova AB
Alzinova is developing a vaccine against the group of substances that are thought to cause Alzheimer's disease (so-called oligomers consisting of amyloid-beta-42). The vaccine, ALZ-101, will now be tested in the clinical phase. The goal is to then find a partner.
Alzinova is developing a vaccine against the group of substances that are thought to cause Alzheimer’s disease (so-called oligomers consisting of amyloid-beta-42). The vaccine, ALZ-101, is now tested in the clinical phase. The goal is to then find a partner.
-
Homepage:
www.alzinova.com
-
Research:
September 17, 2020 (SE)
Contacts
Industry:
BiotechExchange:
First North Growth MarketTicker:
ALZ:SS
Equity Research, Alzinova
September 17, 2020 Research report: Unique Alzheimer’s vaccine with potential in the billions (Swedish)